Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Express Scripts
McKinsey
Colorcon
Johnson and Johnson

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Agomelatine

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Agomelatine?

Agomelatine is an investigational drug.

There have been 17 clinical trials for Agomelatine. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2014.

The most common disease conditions in clinical trials are Depression, Disease, and Depressive Disorder. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and Servier.

There are two hundred and ninety-nine US patents protecting this investigational drug and three international patents.

Recent Clinical Trials for Agomelatine
TitleSponsorPhase
the Efficacy and Safety of Agomelatine in the Patients With Parkinson's DiseaseSecond Affiliated Hospital of Soochow UniversityPhase 4
A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant DepressionJanssen-Cilag International NVPhase 3
Pharmacovigilance in Gerontopsychiatric PatientsHannover Medical SchoolPhase 3

See all Agomelatine clinical trials

Clinical Trial Summary for Agomelatine

Top disease conditions for Agomelatine
Top clinical trial sponsors for Agomelatine

See all Agomelatine clinical trials

US Patents for Agomelatine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Agomelatine   Start Trial Heterocyclic flavone derivatives, compositions, and methods related thereto Emory University (Atlanta, GA)   Start Trial
Agomelatine   Start Trial Memory or learning improvement using peptide and other compositions Transdermal Biotechnology, Inc. (Meriden, CT)   Start Trial
Agomelatine   Start Trial Use of N-acetyl-5-methoxytryptamine or analogues thereof, for promoting the mechanism of implantation of the embryo and related compositions and culture media Ares Trading S.A. (Aubonne, CH)   Start Trial
Agomelatine   Start Trial Eicosapentaenoic acid (EPA) formulations Qualitas Health, Ltd. (Houston, TX)   Start Trial
Agomelatine   Start Trial Compounds and their use as BACE inhibitors AstraZeneca AB (Sodertilje, SE)   Start Trial
Agomelatine   Start Trial Combination of creatine, an omega-3 fatty acid, and citicoline University of Utah Research Foundation (Salt Lake City, UT)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Agomelatine

Drugname Country Document Number Estimated Expiration Related US Patent
Agomelatine China 104487429 2032-07-27   Start Trial
Agomelatine European Patent Office 2877461 2032-07-27   Start Trial
Agomelatine World Intellectual Property Organization (WIPO) 2014018741 2032-07-27   Start Trial
Agomelatine World Intellectual Property Organization (WIPO) 2014159986 2033-03-13   Start Trial
Agomelatine World Intellectual Property Organization (WIPO) 2014160016 2033-03-13   Start Trial
Agomelatine World Intellectual Property Organization (WIPO) 2014160047 2033-03-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Moodys
Merck
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.